



Charles M. Lizza

Phone: (973) 286-6715

Fax: (973) 286-6815

clizza@saul.com

www.saul.com

May 7, 2014

VIA ECF & FEDEX

The Honorable Susan D. Wigenton, U.S.D.J.
United States District Court
Martin Luther King, Jr. Federal Building
50 Walnut Street, Room 5060
Newark, New Jersey 07102

Re: *Celgene Corporation v. Natco Pharma Limited, et al.*
Civil Action No. 10-5197 (SDW)(MCA)

Dear Judge Wigenton:

This firm, together with Quinn Emanuel Urquhart & Sullivan, LLP, Jones Day, and Richard G. Greco PC, represents Plaintiff Celgene Corporation in the above-referenced matter. Enclosed is a Stipulation and [proposed] Order, to which the parties have agreed, regarding infringement of United States Patent Nos. 6,045,501, 6,315,720, 6,561,976, 6,561,977, 6,755,784, and 8,315,886. If the enclosed Stipulation and [proposed] Order meets with Your Honor's approval, we respectfully request that Your Honor sign and have it entered on the docket.

Thank you for Your Honor's kind attention to this matter.

Respectfully yours,

A handwritten signature in black ink, appearing to read "Charles M. Lizza", written in a cursive style.

Charles M. Lizza

Enclosure

cc: All Counsel (via e-mail)

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

CELGENE CORPORATION,

Plaintiff,

v.

**NATCO PHARMA LIMITED,
ARROW INTERNATIONAL LIMITED,
and WATSON LABORATORIES, INC.,**

Defendants.

Civil Action No. 10-5197 (SDW)(MCA)

**Hon. Susan D. Wigenton, U.S.D.J.
Hon. Madeline C. Arleo, U.S.M.J.**

(Filed Electronically)

STIPULATION AND [PROPOSED] ORDER REGARDING INFRINGEMENT

Plaintiff Celgene Corporation (“Celgene”) and Defendants Natco Pharma Limited (“Natco”), Arrow International Limited, and Watson Laboratories, Inc. (collectively, the “Defendants,” which for purposes of this stipulation also includes Watson Pharmaceuticals, Inc., Actavis Inc., Watson Pharma, Inc., and Anda, Inc.), by their undersigned counsel, hereby stipulate and agree that:

WHEREAS Celgene represents that it owns United States Patent Nos. 6,045,501 (the “501 patent”), 6,315,720 (the “720 patent”), 6,561,976 (the “976 patent”), 6,561,977 (the “977 patent”), 6,755,784 (the “784 patent”), and 8,315,886 (the “886 patent”) (collectively, the “Celgene Patents”);

WHEREAS Natco represents that it filed Abbreviated New Drug Application (“ANDA”) No. 201452 seeking approval to engage in the commercial manufacture, use, and/or sale of generic 5, 10, 15, and 25 mg lenalidomide capsules (“Natco’s ANDA Products”) before the expiration of the Celgene Patents;

WHEREAS Defendants proposed to enter a stipulation regarding their infringement of the Celgene Patents;

NOW THEREFORE, the parties, their successors, and assigns hereby stipulate, and will not contest before this Court or any court on appeal, that:

1. If approved by the FDA, the distribution of Natco's ANDA Products in the United States would constitute infringement of each asserted claim of the Celgene Patents, specifically, claims 1 and 3-9 of the '501 patent; claims 1-5, 7-8, 11-19, 21, and 23-28 of the '720 patent; claims 1, 3-6, 8, 10-13, and 15 of the '976 patent; claims 1-7, 9, 11-21, 23, and 25-30 of the '977 patent; claims 1-7, 9, 11-21, 23, and 25-30 of the '784 patent; and claims 1-7 of the '886 patent (collectively, "the Asserted Claims").
2. Nothing herein shall be construed as precluding, restricting, or limiting discovery concerning the validity of the Asserted Claims, including, but not limited to, secondary considerations of nonobviousness.
3. Nothing herein shall be construed as precluding, restricting, or limiting Defendants' obligation to provide discovery concerning ANDA No. 201-452, and to comply with L. Pat. R. 3.6(j).

DATED: May 7, 2014

By: s/ Charles M. Lizza
Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com
wbaton@saul.com

By: s/ James S. Richter
James S. Richter
jrichter@winston.com
Melissa Steedle Bogad
mbogad@winston.com
WINSTON & STRAWN LLP
One Riverfront Plaza, Suite 730
Newark, New Jersey 07102
(973) 848-7676

OF COUNSEL:

F. Dominic Cerrito
Eric Stops
Andrew Chalson
QUINN EMANUEL URQUHART &
SULLIVAN, LLP
51 Madison Avenue, 22nd Floor
New York, New York 10010
(212) 849-7000

Anthony M. Insogna
JONES DAY
12265 El Camino Real
Suite 200
San Diego, California 92130-4096

Richard G. Greco
RICHARD G. GRECO PC
90 State Street, Suite 700
Albany, New York 12207

*Attorneys for Plaintiff
Celgene Corporation*

OF COUNSEL:

George C. Lombardi
Michael K. Nutter
Kevin E. Warner
WINSTON & STRAWN LLP
35 West Wacker Drive
Chicago, Illinois 60601
(312) 558-5600

*Attorneys for Defendants Natco Pharma
Limited, Arrow International Limited, and
Watson Laboratories, Inc., and non-
parties Watson Pharmaceuticals, Inc,
Actavis, Inc., Watson Pharma, Inc, and
Anda, Inc.*

SO ORDERED this _____ day of _____.

Honorable Susan D. Wigenton,
United States District Court Judge